Cardiff Oncology
CRDF
55 hedge funds and large institutions have $11.6M invested in Cardiff Oncology in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 16 increasing their positions, 7 reducing their positions, and 9 closing their positions.
129% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 7
8% more capital invested
Capital invested by funds: $10.7M → $11.6M (+$901K)
1.45% less ownership
Funds ownership: 17.23% → 15.78% (-1.5%)
8% less funds holding
Funds holding: 60 → 55 (-5)
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
85% less call options, than puts
Call options by funds: $37K | Put options by funds: $251K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$1.12M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$370K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$81.2K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$71.2K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$38K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$1.05M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$314K |
| 3 |
Renaissance Technologies
New York
|
-$274K |
| 4 |
Mercer Global Advisors
Denver,
Colorado
|
-$207K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$138K |
CRDF Hedge Fund Activity: Q1 2023 in Review
55 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q1 2023, worth a combined $11.6M — up 8.4% from $10.7M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of CRDF and 5 opened new positions — a net loss of 4 holders — while 7 trimmed existing stakes and 16 added.
The largest buyer was Citigroup, adding an estimated $1.12M. The largest seller was Artal Group, exiting entirely with an estimated $1.05M sold.
- 55 institutional investors held Cardiff Oncology (CRDF) as of Q1 2023, down from 60 in Q4 2022.
- Funds reported $11.6M of Cardiff Oncology stock for Q1 2023, up 8.4% quarter-over-quarter.
- 5 funds opened new Cardiff Oncology positions in Q1 2023 and 9 closed out, a net change of -4 holders.
- The largest Cardiff Oncology buyer in Q1 2023 was Citigroup, an estimated $1.12M added.
- The largest Cardiff Oncology seller in Q1 2023 was Artal Group, an estimated $1.05M sold.
Based on aggregated 13F filings for Q1 2023.